



## ***Craig W. Olshan***

**PARTNER**

**Silicon Valley**

**P +1 650 463 5413**

## **Craig is a partner in the Executive Compensation group.**

Craig advises clients on executive compensation and employee benefits issues in connection with complex corporate transactions, including mergers and acquisitions, sales, spin-offs, public offerings, and other private and public business combinations.

Craig has extensive experience in the design, modification and negotiation of compensation arrangements, including employment agreements, equity- and cash-based incentive plans and separation agreements.

He counsels on tax planning with respect to golden parachute excise tax issues, and tax rules and consequences relating to nonqualified deferred compensation. Craig also advises clients on corporate governance matters and SEC guidelines governing executive compensation disclosure and reporting.

## Credentials

### EDUCATION

- University of Pennsylvania Law School, J.D.
- Williams College, B.A.

### BAR ADMISSIONS

- California
- New York

## Focus Areas

Executive Compensation

## Related News & Insights

### CLIENT NEWS

Ripple Announces Agreement to Acquire Hidden Road for \$1.25B

### CLIENT NEWS

Gunderson Dettmer Represented Tabular in Acquisition by Databricks

### CLIENT NEWS

Tonal Announces \$130M Financing and New CEO Krystal Zell

### FIRM NEWS

Gunderson Dettmer Announces 11 New Elected Partners

### CLIENT NEWS

Payments Infrastructure Company Geopagos Announces \$35M Financing led by Riverwood Capital

### CLIENT NEWS

TeneoTwo Enters into Agreement to be Acquired by AstraZeneca

CLIENT NEWS

Ancora Biotech Announces \$60M Series A Co-Led by Lightspeed Venture Partners and SR One

CLIENT NEWS

BehavioSec® Announces Acquisition by RELX

EVENTS

Grand Central Tech: Executive Compensation Workshop

CLIENT NEWS

Technisys Acquisition by SoFi Technologies

CLIENT NEWS

Carto Raises \$61M Series C Financing

CLIENT NEWS

Gunderson Dettmer Advises Theseus Pharmaceuticals on Initial Public Offering

CLIENT NEWS

Teneobio Acquired by Amgen for \$2.5B